Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: a case series

The discovery of kinase gene rearrangements as oncogenic drivers in non-small cell lung carcinomas (NSCLCs), and the subsequent development of targeted therapies (TTs) have dramatically changed the landscape of this small subset of malignancies. Development of potent tyrosine-kinase inhibitors (TKIs) targeting fusions involving the genes ROS1, anaplastic lymphoma kinase (ALK), and neurotrophic tyrosine receptor kinase (NTRK) have provided overall response rates (ORRs) as high as 70-80% in metastatic disease, overcoming chemotherapy regimens as first-line treatment in this setting [1].

Source: Lung Cancer - October 23, 2019 Category: Cancer & Oncology Authors: Maur ício Fernando Silva Almeida Ribeiro, João Victor Machado Alessi, Leandro Jonata Carvalho Oliveira, Aline Bobato Lara Gongora, Karina Perez Sacardo, Bruna Migliavacca Zucchetti, Andrea Kazumi Shimada, Felipe de Galiza Barbosa, Olavo Feher, Artur Kat Source Type: research